Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Zolmitriptan OD



What is Zolmitriptan OD?

Zolmitriptan orally disintegrating tablets contain zolmitriptan, which is a selective 5-hydroxytryptamine(5-HT) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and  has  the  following chemical structure:

The molecular formula is C­­H­­N­O­, representing a molecular weight of 287.36. Zolmitriptan is white to cream colored crystalline powder that is freely soluble in methanol, slightly soluble in ethyl acetate and very slightly soluble in water.  Zolmitriptan orally disintegrating tablets are available for oral administration as 2.5 mg and 5 mg, white colored, round shaped, flat faced, beveled edged tablets. Each orally disintegrating tablet contains acesulfame potassium, aminomethacrylate copolymer, colloidal silicon dioxide, crospovidone, low-substituted hydroxypropyl cellulose, magnesium aluminometasilicate, magnesium stearate, mannitol, peppermint flavor, sodium lauryl sulfate and talc.

What does Zolmitriptan OD look like?

What are the available doses of Zolmitriptan OD?

•   Orally Disintegrating Tablets: 2.5 mg and 5 mg ()

What should I talk to my health care provider before I take Zolmitriptan OD?

How should I use Zolmitriptan OD?

Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults.

The recommended starting dose of zolmitriptan is 1.25 mg or 2.5 mg.  The 1.25 mg dose can be achieved  by  manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of zolmitriptan is 5 mg. 

In controlled clinical trials, a greater proportion of patients had headache response following a 2.5 mg or 5 mg dose than following a 1 mg dose. There was little added benefit from the 5 mg dose compared to the 2.5 mg dose, but adverse reactions were more frequent with the 5 mg dose. If the migraine has not resolved by 2 hours after taking zolmitriptan, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose is 10 mg in any 24-hour period. The safety of zolmitriptan in the treatment of an average of more than three migraines in a 30-day period has not been established.

What interacts with Zolmitriptan OD?

Sorry No Records found

What are the warnings of Zolmitriptan OD?

Sorry No Records found

What are the precautions of Zolmitriptan OD?

Sorry No Records found

What are the side effects of Zolmitriptan OD?

Sorry No records found

What should I look out for while using Zolmitriptan OD?

Zolmitriptan is contraindicated in patients with:

What might happen if I take too much Zolmitriptan OD?

There is no experience with acute overdose of zolmitriptan. Clinical study subjects who received single 50 mg oral doses of zolmitriptan commonly experienced sedation.  There is no specific antidote to zolmitriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring  adequate  oxygenation  and  ventilation,  and monitoring and support of the cardiovascular system.  The elimination half-life of zolmitriptan is 3 hours [see ]; therefore,   monitor   patients   after overdose with zolmitriptan  for at least 15 hours or until symptoms or signs resolve.  It is unknown what effect hemodialysis or peritoneal dialysis has on the plasma concentrations of zolmitriptan.

How should I store and handle Zolmitriptan OD?

2.5 mg Orally Disintegrating Tablets5 mg Orally Disintegrating Tablets2.5 mg Orally Disintegrating Tablets5 mg Orally Disintegrating Tablets


Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Zolmitriptan binds with high affinity to human recombinant 5­-HT and 5-HT receptors, and moderate affinity for 5-HT receptors. The N-desmethyl metabolite also has high affinity for 5-HT and moderate affinity for 5-HT receptors.   Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Non-Clinical Toxicology
Zolmitriptan is contraindicated in patients with:

Caution should be exercised when propranolol hydrochloride extended-release capsules are administered with drugs that have an affect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity (see in ).


Zolmitriptan is contraindicated in patients with ischemic or vasospastic coronary artery disease (CAD). There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of zolmitriptan. Some of these reactions occurred in patients without known CAD. 5-HT agonists including zolmitriptan may cause coronary artery vasospasm (Prinzmetal Angina), even in patients without a history of CAD.  Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD)  prior to receiving zolmitriptan. Do not administer zolmitriptan  if there is evidence of CAD or coronary artery vasospasm [see  ]  For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administrating the first zolmitriptan dose in a medically-supervised setting and performing an electrocardiogram (ECG)  immediately following zolmitriptan administration. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of zolmitriptan.

The following adverse reactions are described elsewhere in other sections of the prescribing information:



This information is obtained from the National Institute of Health's Standard Packaging Label drug database.

While we update our database periodically, we cannot guarantee it is always updated to the latest version.



Rate this treatment and share your opinion

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment


Click the stars to rate this treatment

This medication has worked for me.

This medication has been easy for me to use.

Overall, I have been satisfied with my experience.

Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:


Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72






A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).